Australian Regulators Recommend Biosimilar Substitution without Notification
Australian pharmacists could soon substitute a biosimilar infliximab for its reference product without prescribing physicians’ –or even patients’—knowledge.
Preemie Matters National Policy Summit
The Institute for Patient Access and the National Coalition for Infant Health welcomed health care providers, advocates, parents and members of Congress for the Preemie Matters National Policy Summit in Washington, DC on June 24-25, 2015. The summit featured remarks from preemie mom and CNN host Nancy Grace, who shared her personal and […]
FDA Guidance Suggests Distinct Names for Biosimilars
The FDA has issued new guidance that proposes giving distinct non-proprietary names to biologics and biosimilars.
Proposed Co-pay Hike for Military Families Stirs Debate
When Congress resumes session in September, it must also resume negotiations on a tense topic—raising co-pay limits for veterans and military families relying on Tricare health coverage.
FDA’s Oxycodone Decision Offers New Prescribing Information for Treating Kids
Physicians who prescribe opioid analgesics for kids with severe pain will now have the benefit of FDA guidance on pediatric dosing and safety.
Cancer Patients’ Cost Burden Fuels Continued Debate
Rising costs have brought public debate on patient access to cancer medications to a head.
New Study: Preterm Infants without Prophylaxis Suffer Severe RSV
New data confirms what neonatal health care providers and preemie advocates feared – without access to preventative care against respiratory syncytial virus, pre-term infants are suffering severe cases of the deadly disease unnecessarily.
Patients with Respiratory Conditions Struggle to Access Needed Medications
For many Americans with respiratory conditions, the struggle to breathe is now exacerbated by the struggle to pay out-of-pocket expenses for the medications that alleviate their symptoms.
GAfPA Encourages Standards-based Guidelines for Colombia’s Biosimilars
Colombian regulators’ ill-defined “alternative approach” to approving biosimilar medicines has the country’s patients unsettled.
“Best Shot” White Paper Explores Challenges of Senior Citizen Vaccination
If you thought vaccines were just for babies, think again.
